For research use only. Not for therapeutic Use.
SR-4835（Cat No.:I017729）is a selective dual inhibitor targeting cyclin-dependent kinase 12 (CDK12) and CDK13, which play essential roles in transcriptional regulation and DNA damage response. By inhibiting these kinases, SR-4835 impairs the expression of key genes involved in DNA repair, making cancer cells more susceptible to DNA-damaging agents. This compound is particularly valuable in research focused on cancer therapies, especially for tumors with mutations affecting DNA repair pathways. SR-4835’s unique mechanism provides potential for enhancing the efficacy of combination treatments in oncology.
| Catalog Number | I017729 |
| CAS Number | 2387704-62-1 |
| Molecular Formula | C₂₁H₂₀Cl₂N₁₀O |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | N-[(5,6-dichloro-1H-benzimidazol-2-yl)methyl]-9-(1-methylpyrazol-4-yl)-2-morpholin-4-ylpurin-6-amine |
| InChI | InChI=1S/C21H20Cl2N10O/c1-31-10-12(8-26-31)33-11-25-18-19(29-21(30-20(18)33)32-2-4-34-5-3-32)24-9-17-27-15-6-13(22)14(23)7-16(15)28-17/h6-8,10-11H,2-5,9H2,1H3,(H,27,28)(H,24,29,30) |
| InChIKey | FSELUFUYNUNZKD-UHFFFAOYSA-N |
| SMILES | CN1C=C(C=N1)N2C=NC3=C(N=C(N=C32)N4CCOCC4)NCC5=NC6=CC(=C(C=C6N5)Cl)Cl |
| Reference | [1]. Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6. |
